<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="576">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153655</url>
  </required_header>
  <id_info>
    <org_study_id>LIPostC</org_study_id>
    <nct_id>NCT05153655</nct_id>
  </id_info>
  <brief_title>Ischemic Post-conditioning in Acute Ischemic Stroke Thrombectomy</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Safety and Tolerability of Local Ischemic Post-conditioning in Patients With Acute Ischemic Stroke After Mechanical Thrombectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemic post-conditioning is a neuroprotective strategy that has been proven to attenuate&#xD;
      reperfusion injury in animal models of stroke. The purpose of this proof-of-concept study is&#xD;
      to determine the safety and tolerability of ischemic post-conditioning in patients with acute&#xD;
      ischemic stroke who are treated with mechanical thrombectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with major response</measure>
    <time_frame>Immediately after intervention on the day of ischemic post-conditioning</time_frame>
    <description>Major response is any of the following:&#xD;
Vessel perforation or rupture;&#xD;
Reocclusion of the culprit vessel after post-conditioning;&#xD;
Vessel dissection;&#xD;
Severe vasospasm;&#xD;
Ischemic post-conditioning related thrombotic events;&#xD;
Rupture of the balloon used for post-conditioning.&#xD;
In the 3 + 3 design, 3 subjects are recruited for a given ischemic post-conditioning dose level. The trial is stopped if ≥ 2 of 3 subjects at a given dose level show major response. If only 1 of 3 subjects shows major response, 3 more subjects are recruited at a given dose level and a major response in any of them will stop the trial. Otherwise, same procedure is followed for the next ischemic post-conditioning dose level. Maximum tolerable dose will be the dose at the level before stopping of the trial.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Ischemic post-conditioning group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The safety and tolerability of ischemic post-conditioning will be investigated using 3+3 dose-escalation trial design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local ischemic post-conditioning</intervention_name>
    <description>Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0 &quot; 1 &quot; 2 &quot; 3 &quot; 4 &quot; 5 min.</description>
    <arm_group_label>Ischemic post-conditioning group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years;&#xD;
&#xD;
          -  Acute ischemic stroke caused by middle cerebral artery M1 segment occlusion;&#xD;
&#xD;
          -  Successful recanalization (mTICI 2b/3) after endovascular thrombectomy that confirmed&#xD;
             by digital subtraction angiography;&#xD;
&#xD;
          -  Written informed consent provided by the patients or their legal relatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known diagnosis or clinical suspicion of cerebral vasculitis or fibromuscular&#xD;
             dysplasia;&#xD;
&#xD;
          -  Difficulty in reaching the designated position of the balloon used for ischemic&#xD;
             post-conditioning;&#xD;
&#xD;
          -  Stenting in the middle cerebral artery as rescue therapy during the thrombectomy&#xD;
             procedures;&#xD;
&#xD;
          -  &gt; 2 times of balloon dilations as rescue therapy due to angioplasty during the&#xD;
             thrombectomy procedures;&#xD;
&#xD;
          -  Moderate or severe residual stenosis (≥ 50%) of the culprit artery after&#xD;
             recanalization;&#xD;
&#xD;
          -  Difficulty in complying with ischemic post-conditioning or other conditions that the&#xD;
             investigator considered inappropriate for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xunming Ji, M.D.</last_name>
    <phone>010-83198952</phone>
    <email>jixm@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenbo Zhao, M.D.</last_name>
    <email>zhaowb@xwh.ccmu.edu.cn</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>ischemic postconditioning</keyword>
  <keyword>endovascular thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

